Molbio Diagnostics Reports Rs 52.7 Crore Profit in Q1 Post-IPO
Molbio Diagnostics posts Rs 52.7 crore profit in Q1 FY27, driven by Truenat test-kit sales.
Molbio Diagnostics, a recently listed company, has reported a profit of Rs 52.74 crore for the first quarter of the fiscal year 2027. This marks a significant turnaround from the Rs 23.94 crore loss recorded during the same period last year, according to a regulatory filing by the company.
Impact of Truenat Test-Kit Sales
The company attributes its improved financial performance to the increased sales of its Truenat test-kits. In the June quarter, the volume of Truenat test-kits surged to 62.4 lakh units, a substantial increase from the 7.9 lakh units sold in the previous year. Truenat kits are known for their quick and accurate detection of various infectious diseases at the point of care, which has likely contributed to their rising demand.
Molbio Diagnostics raised approximately Rs 940 crore through an Initial Public Offering (IPO) before its listing on the stock exchanges on August 17. This financial boost has apparently aided the company in achieving robust growth in both revenue and profitability.
Financial Performance and Future Outlook
The total income for the quarter stood at Rs 411.48 crore, a significant increase from Rs 100.47 crore reported in the first quarter of the previous fiscal year. This growth underscores the company's successful market expansion and product acceptance.
Sriram Natarajan, Executive Director and CEO of Molbio Diagnostics, expressed optimism about the company's performance. "FY27 is a milestone year for Molbio, marking our transition to a listed company. We have begun the year on a strong note, with healthy growth across both revenue and profitability in Q1," he stated.
The company's strategic focus on expanding the reach and application of its Truenat test-kits appears to be paying off, positioning Molbio Diagnostics as a key player in the diagnostics industry.
As the company continues to leverage its IPO proceeds, industry watchers will be keen to see how Molbio Diagnostics sustains this growth trajectory in the coming quarters.